1. Home
  2. MDAI vs GRCE Comparison

MDAI vs GRCE Comparison

Compare MDAI & GRCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDAI
  • GRCE
  • Stock Information
  • Founded
  • MDAI 2013
  • GRCE 2002
  • Country
  • MDAI United States
  • GRCE United States
  • Employees
  • MDAI N/A
  • GRCE N/A
  • Industry
  • MDAI Medical/Dental Instruments
  • GRCE
  • Sector
  • MDAI Health Care
  • GRCE
  • Exchange
  • MDAI Nasdaq
  • GRCE NYSE
  • Market Cap
  • MDAI 51.5M
  • GRCE 42.4M
  • IPO Year
  • MDAI N/A
  • GRCE N/A
  • Fundamental
  • Price
  • MDAI $2.52
  • GRCE $3.35
  • Analyst Decision
  • MDAI Strong Buy
  • GRCE Strong Buy
  • Analyst Count
  • MDAI 2
  • GRCE 1
  • Target Price
  • MDAI $4.75
  • GRCE $12.00
  • AVG Volume (30 Days)
  • MDAI 762.2K
  • GRCE 63.7K
  • Earning Date
  • MDAI 08-11-2025
  • GRCE 08-15-2025
  • Dividend Yield
  • MDAI N/A
  • GRCE N/A
  • EPS Growth
  • MDAI N/A
  • GRCE N/A
  • EPS
  • MDAI N/A
  • GRCE N/A
  • Revenue
  • MDAI $29,962,000.00
  • GRCE N/A
  • Revenue This Year
  • MDAI N/A
  • GRCE N/A
  • Revenue Next Year
  • MDAI $15.15
  • GRCE N/A
  • P/E Ratio
  • MDAI N/A
  • GRCE N/A
  • Revenue Growth
  • MDAI 55.21
  • GRCE N/A
  • 52 Week Low
  • MDAI $0.82
  • GRCE $1.75
  • 52 Week High
  • MDAI $3.25
  • GRCE $4.97
  • Technical
  • Relative Strength Index (RSI)
  • MDAI 54.88
  • GRCE N/A
  • Support Level
  • MDAI $2.63
  • GRCE N/A
  • Resistance Level
  • MDAI $2.95
  • GRCE N/A
  • Average True Range (ATR)
  • MDAI 0.23
  • GRCE 0.00
  • MACD
  • MDAI -0.04
  • GRCE 0.00
  • Stochastic Oscillator
  • MDAI 38.38
  • GRCE 0.00

About MDAI Spectral AI Inc.

Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.

About GRCE GRACE THERAPEUTICS INC

Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage. Other products are GTx-102 Ataxia-Telangiectasia, GTx-101 Postherpetic Neuralgia, and GTx-201.

Share on Social Networks: